Our first quarter results set the foundation for a strong 2023. It is great to be with you today to discuss the start of 2023 and the progress that we're making. Now I'll turn the call over to Adam Schechter. We have no obligation to provide any updates to these forward-looking statements even if our expectations change. More information is included in our most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q and in the company's other filings with the SEC. These forward-looking statements include, but are not limited to, statements with respect to the estimated 2023 guidance and the related assumptions, the proposed spinoff of the clinical development business, the impact of various factors on the company's businesses, operating and financial results, cash flows and/or financial condition, including the COVID-19 pandemic and general economic and market conditions, future business strategies, expected savings and synergies, including from the LaunchPad initiative, acquisitions and other transactions and opportunities for future growth.Įach of the forward-looking statements are subject to change based on a use factors, many of which are beyond our control. This morning, in the Investor Relations section of our website at we posted both our press release and an Investor Relations presentation with additional information on our business and operations, which include a reconciliation of the non-GAAP financial measures to the GAAP financial measures discussed during today's call.Īdditionally, we are making forward-looking statements. With me today are Adam Schechter, Chairman and Chief Executive Officer and Glenn Eisenberg, Executive Vice President and Chief Financial Officer. As detailed in today's press release, there will be a replay of this conference call available via telephone and Internet. Good morning, and welcome to Labcorp's First Quarter 2023 Conference Call. I would now like to hand the conference over to Chas Cook. Welcome to Labcorp's Q1 2023 Earnings Conference Call.
Timothy Ian Daley Associate Analyst Wells Fargo Securities, LLC, Research Division Presentation Patrick Bernard Donnelly Senior Analyst Citigroup Inc., Research Division Kevin Caliendo Equity Research Analyst of Healthcare IT and Distribution UBS Investment Bank, Research Division Jack Meehan Research Analyst Nephron Research LLC Incorporated, Research DivisionĮrin Elizabeth Wilson Wright Equity Analyst Morgan Stanley, Research Division Eisenberg CFO & Executive VP Laboratory Corporation of America HoldingsĪnn Kathleen Hynes MD of Americas Research Mizuho Securities USA LLC, Research Divisionīrian Gil Tanquilut Senior Equity/Stock Analyst Jefferies LLC, Research Divisionĭerik De Bruin MD of Equity Research BofA Securities, Research DivisionĮric White Coldwell Senior Research Analyst Robert W. Schechter President, CEO & Chairman Laboratory Corporation of America HoldingsĬhas Cook VP of IR Laboratory Corporation of America Holdings LabCorp is headquartered in Burlington, North Carolina, the US.Adam H. The company has operations across the US, Belgium, China, Singapore, the UK, and other countries. It offers services to managed care organizations, physicians, hospitals, government agencies, and biotechnology and pharmaceutical companies through a network of primary laboratories and patient service centers. It also offers drug development services through Covance. Its services include general and specialty laboratory testing, bone marrow and human leukocyte antigen (HLA) testing, clinical trials services, drug testing services, deoxyribonucleic acid (DNA) identification services, forensic identity services, insurance health plan services, paternity testing services, patient services, personalized medicine, and hospital services. The company offers clinical diagnostics laboratory services such as core testing, genomic and esoteric testing. It focuses on the development and commercialization of a range of diagnostic technologies and testing services. Laboratory Corp of America Holdings (LabCorp) is a provider of clinical laboratory services and end-to-end drug development support.
0 kommentar(er)
